PBM executive: Industry has been discussing end of rebates for a ‘long, long time’
Though the Trump administration’s steps to end drug rebates have been met with outrage from pharmacy benefit managers (PBMs), these companies have been talking about a future without rebates for a long time, experts say.
Byron Mickle, senior vice president for sales and marketing at Navitus Health Solutions, a Wisconsin-based PBM, said during a panel at the World Health Care Congress that eliminating the rebate model is a good foundation for policy to address other issues in drug pricing, such as the cost of specialty drugs.
Stay Informed and Connected
Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.
Navigating with a trusted partner
Now Available: 9th Annual Drug Trend Report
Our Drug Trend Report provides a clear view of the trends shaping pharmacy benefits today, along with strategies that are delivering real savings without compromising care.
Related blogs
Navigating Healthcare and Improving Outcomes
Navigating the Key Drivers of Drug Spend and Utilization
Prescription drug spending rose by 11.4% in 2024, reshaping how plan sponsors approach their pharmacy benefit strategy. Costs climbed as existing therapies expanded, new treatments entered the market and coverage decisions shifted pricing dynamics. For…
